News Search Results
Sep 24, 2025, 07:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 24, 2025, 02:45 ET New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies
Beach, FL, US.Smith P, Huck C, Wegert V, et al. Low-dose, subcutaneous anti-CD20 therapy effectively depletes B-cells and ameliorates CNS autoimmunity. Poster presentation at: the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting 2016; September
More news about: Novartis Pharmaceuticals Corporation
Sep 24, 2025, 02:00 ET Corero Network Security Expands Partnership with Netceed to Strengthen UK Network Resilience
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced the expansion of its strategic
More news about: Corero Network Security
Sep 23, 2025, 18:44 ET Cohen & Steers Closed-End Funds Declare Distributions for October, November and December 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 23, 2025, 11:30 ET Inna Topiler, Leading Hashimoto's & Thyroid Expert, Launches ThyroLove: A Revolutionary Thyroid Supplement
NEW YORK, Sept. 23, 2025 /PRNewswire/ -- Inna Topiler, MS, CNS, founder of Complete Nutrition and Wellness and host of Thyroid Mystery Solved today announced the launch of ThyroLove, a breakthrough thyroid and immune
More news about: Complete Nutrition and Wellness
Sep 23, 2025, 07:00 ET Corero Network Security and Atlantic Data Security Form Strategic Business Resiliency Partnership
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced a new strategic partnership
More news about: Corero Network Security
Sep 22, 2025, 10:51 ET Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
innovative solutions in the CNS field, some of which are based on advanced technologies resulting from strategic alliances. Neuraxpharm remains focused on innovation and investment in new solutions with the goal of improving the quality of life for people with CNS disorders. The company is committed
More news about: Neuraxpharm
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
into only three categories: Astrocytoma, IDH-mutant (CNS WHO grades 2-4) Oligodendroglioma, IDH-mutant and1p19q-codeleted (CNS WHO grades 2-3) Glioblastoma, IDH-wildtype (CNS WHO grade 4) VORANIGO IMPORTANT SAFETY INFORMATION FOR U.S. PATIENTS
More news about: Servier Pharmaceuticals
Sep 22, 2025, 07:45 ET Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses
in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death.Because of the risks of CNS depression and abuse and misuse,
More news about: Jazz Pharmaceuticals plc
Sep 18, 2025, 18:37 ET Faruqi & Faruqi Reminds Alto Neuroscience Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 19, 2025 - ANRO
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Sep 18, 2025, 17:31 ET NF-κB Inhibitors Market to Witness Accelerated Expansion Across the 7MM through 2034 | DelveInsight
and neurological applications Because NF-κB signaling is implicated in Alzheimer's, Parkinson's, long-COVID neurological symptoms and other CNS disorders, pipeline activity aimed at neurodegeneration (and the need for blood-brain-barrier-permeable molecules) is expanding market opportunity. BioVie's
More news about: DelveInsight Business Research, LLP
Sep 18, 2025, 16:30 ET Cohen & Steers and Lincoln Property Company Form Joint Venture on Cityline at Tenley Retail Center in Washington, D.C.
NEW YORK, Sept. 18, 2025 /PRNewswire/ -- Cohen & Steers (NYSE: CNS) announced today that funds managed by the Private Real Estate Group of Cohen & Steers and Lincoln Property Company have entered into a joint venture
More news about: Cohen & Steers, Inc.
Sep 18, 2025, 11:57 ET Mikart and Nano PharmaSolutions Announce Positive Interim Data from NT-301 Phase 1 Trial and Expansion of NanoTransformer® Manufacturing Capabilities
NanoTransformer® platform designed to improve the solubility and bioavailability of poorly water-soluble molecular drugs. NPS develops its own pipeline of CNS medicines while partnering with pharmaceutical companies to enhance delivery of challenging APIs. The NanoTransformer® technology uses a patented physical
More news about: Mikart, LLC
Sep 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 17, 2025, 11:03 ET Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.
cell-specific promoters, enabling durable rescue of gene expression with minimal off-target effects. Regel's lead programs focus on severe pediatric CNS disorders, including Dravet Syndrome and SCN2A haploinsufficiency. The company is headquartered in Cambridge, MA. For
More news about: Regel Therapeutics Inc.
Sep 17, 2025, 08:30 ET MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
positioned as a potential treatment for ADP based on the favorable safety and tolerability profile observed in healthy elderly volunteers in Phase 1 whose CNS exposures achieved or exceeded levels that we anticipate being clinically relevant," said Erin Foff, M.D., Ph.D., Chief
More news about: MapLight Therapeutics, Inc.
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
miR23b - - Funding to also advance a broader pipeline of targeted RNA medicines across areas of high unmet need in muscular, CNS, cardiac conditions - VALENCIA, Spain,
More news about: ARTHEx Biotech
Sep 16, 2025, 08:00 ET Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
synergistic and durable anti-inflammatory effects. Highlights from Cohort 1: COYA 303 produced significant systemic and CNS immunomodulatory effects in the LPS model of inflammationCOYA 303 significantly (a) enhanced Treg numbers and suppressive function, (b) reduced
More news about: Coya Therapeutics, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers Appoints John Gellatly as Senior Advisor
YORK, Sept. 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of John Gellatly as Senior Advisor. Based in London,
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers ernennt John Gellatly zum Senior Advisor
YORK, 16. September 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) gab heute die Ernennung von John Gellatly zum Senior Advisor bekannt. Von London aus wird
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers benoemt John Gellatly tot senior adviseur
YORK, 16 september 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) kondigde vandaag de benoeming aan van John Gellatly als senior adviseur. Vanuit Londen zal de heer Gellatly nauw samenwerken
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers nomme John Gellatly comme conseiller principal
NEW YORK, 16 septembre 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE : CNS) a annoncé aujourd'hui la nomination de John Gellatly au poste de conseiller principal. Basé à Londres, M. Gellatly travaillera en étroite collaboration
More news about: Cohen & Steers, Inc.
Sep 15, 2025, 16:20 ET Cohen & Steers Announces Chief Financial Officer Transition
YORK, Sept. 15, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri, Executive Vice President and Chief Financial Officer, has provided notice of his decision
More news about: Cohen & Steers, Inc.
Sep 15, 2025, 08:00 ET The Korea Industry Daily: Industrial AI EXPO 2025 Concludes, Marking Milestone in Korea's AI-Driven Industrial Transformation
contributions to industrial digital transformation and AI utilization. Government officials and industry leaders—including executives from HD Hyundai, LG CNS, Microsoft Korea, Dassault Systèmes, HP Korea, Salesforce, and major domestic institutions—attended the opening ceremony, underscoring collective commitment
More news about: THE KOREA INDUSTRY DAILY
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
SPRAVATO® with certain medicine may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson